Top

Published in:

Open Access 01-12-2012 | Meeting abstract

Targeted therapy in head/neck and gastric cancers

Author: Chung-Tsen Hsueh

Published in: Journal of Hematology & Oncology | Special Issue 1/2012

Excerpt

The epidermal growth factor receptor (EGFR/HER1) is a member of the erbB family of receptor tyrosine kinase proteins, which also includes HER2, HER3, and HER4. EGFR is almost universally expressed in squamous cell carcinoma of head and neck (SCCHN), and high levels of expression have been correlated with a poor clinical prognosis [1]. Cetuximab, an IgG1 monoclonal antibody against EGFR, has demonstrated improved survival and disease control when used in combination with radiation therapy for the treatment of locally advanced SCCHN, and in combination with platinum-based chemotherapy in recurrent or metastatic SCCHN [2‐4]. Additionally, single-agent cetuximab is active and provides good disease control rate and duration in platinum-refractory SCCHN [5]. Comparison of cetuximab versus cisplatin concurrently with radiotherapy is under investigation in patients with human papillomavirus-associated oropharyngeal cancer, who have better prognosis and may benefit from less toxic treatment [6]. …

Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62 (24): 7350-7356.PubMed

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354 (6): 567-578. 10.1056/NEJMoa053422.CrossRefPubMed

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11 (1): 21-28. 10.1016/S1470-2045(09)70311-0.CrossRefPubMed

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008, 359 (11): 1116-1127. 10.1056/NEJMoa0802656.CrossRefPubMed

Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007, 25 (16): 2171-2177. 10.1200/JCO.2006.06.7447.CrossRefPubMed

Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer (clinicaltrials.gov identifier: NCT01302834). [http://clinicaltrials.gov/ct2/show/NCT01302834]

Park D, Yun J, Park J, Oh S, Kim H, Cho Y, Sohn C, Jeon W, Kim B, Yoo C: HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences. 2006, 51 (8): 1371-1379. 10.1007/s10620-005-9057-1.CrossRefPubMed

Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology. 2007, 59 (6): 795-805. 10.1007/s00280-006-0337-z.CrossRefPubMed

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010, 376 (9742): 687-697. 10.1016/S0140-6736(10)61121-X.CrossRefPubMed

10.

Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT: Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol. 2010, 3: 31-10.1186/1756-8722-3-31.PubMedCentralCrossRefPubMed

11.

A phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma (clinicaltrials.gov identifier: NCT01196390 ). [http://clinicaltrials.gov/ct2/show/NCT01196390]

12.

HerFLOT: Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin in combination With trastuzumab in patients With HER2-positive, locally advanced, resectable adenocarcinoma of the gastroesophageal junction or stomach (clinicaltrials.gov identifier: NCT01472029). [http://clinicaltrials.gov/ct2/show/NCT01472029]

13.

An open-label, multi-center study to evaluate the disease free survival rate of a perioperative combination of capecitabine (xeloda), trastuzumab and oxaliplatin (XELOX- Trastuzumab) in patients with resectable gastric or gasro-esophageal junction adenocarcinoma (clinicaltrials.gov identifier: NCT01130337). [http://clinicaltrials.gov/ct2/show/NCT01130337]

14.

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011, 366 (2): 109-119.CrossRefPubMed

15.

An open-label, randomized, multicenter phase IIa study evaluating pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer (clinicaltrials.gov identifier: NCT01461057). [http://clinicaltrials.gov/ct2/show/NCT01461057]

Title: Targeted therapy in head/neck and gastric cancers
Author: Chung-Tsen Hsueh
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue Special Issue 1/2012
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-5-S1-A1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Utilizing CD30 expression as a rational target for therapy of lymphoma

Recent advances in myelodysplasia: update from 2011 ASH annual meeting

Restoration of T cell tolerance in primary ITP

Targeting p53 by small molecule p53 activators in multiple myeloma

T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting

Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer